相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer
Ying Fan et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)
Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of Wnt-beta-catenin-STAT3 signaling
Shunfeng Hu et al.
CELL DEATH AND DIFFERENTIATION (2022)
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Alex Friedlaender et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Noninvasive proteomic biomarkers for alcohol-related liver disease
Lili Niu et al.
NATURE MEDICINE (2022)
Multiplex Droplet Digital PCR Assay for Detection of MET and HER2 Genes Amplification in Non-Small Cell Lung Cancer
Igor P. Oscorbin et al.
CANCERS (2022)
MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome
Wei Yin et al.
CANCERS (2022)
Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC
Jan Trost Jorgensen et al.
CANCERS (2022)
Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision
Gillianne G. Y. Lai et al.
CANCER TREATMENT REVIEWS (2022)
Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors
James P. Solomon et al.
CLINICAL CANCER RESEARCH (2022)
Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis
Zemin Ren et al.
BLOOD (2021)
Exosome-based liquid biopsies in cancer: opportunities and challenges
W. Yu et al.
ANNALS OF ONCOLOGY (2021)
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
Lun-Xi Peng et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)
Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development
Abhijit Pal et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Prediction and prognostic significance of ALOX12B and PACSIN1 expression in gastric cancer by genome-wide RNA expression and methylation analysis
Zhiping Liu et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)
SnapShot: Clinical proteomics
Yi Zhu et al.
CELL (2021)
Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
Mohamed Eltahir et al.
CANCERS (2021)
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Lecia Sequist et al.
LANCET ONCOLOGY (2020)
ALOX12B promotes carcinogenesis in cervical cancer by regulating the PI3K/ERK1 signaling pathway
Tao Jiang et al.
ONCOLOGY LETTERS (2020)
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Yi-Long Wu et al.
LANCET RESPIRATORY MEDICINE (2020)
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
Michael A. Gillette et al.
CELL (2020)
MET-dependent solid tumours - molecular diagnosis and targeted therapy
Robin Guo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy
Satoshi Yamashita et al.
SCIENTIFIC REPORTS (2020)
Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma
Xian Lin et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer
Gillianne Gy Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium
Robin Guo et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Clinical potential of mass spectrometry-based proteogenomics
Bing Zhang et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy
Henning Reis et al.
CLINICAL LUNG CANCER (2018)
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas
Xavier Mignard et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
Revisiting biomarker discovery by plasma proteomics
Philipp E. Geyer et al.
MOLECULAR SYSTEMS BIOLOGY (2017)
An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia
O. Zimmermannova et al.
ONCOGENE (2017)
Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
Sinead A. Noonan et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer
Anna Li et al.
LUNG CANCER (2015)
MET Amplification Status in Therapy-Naive Adeno- and Squamous Cell Carcinomas of the Lung
Hans-Ulrich Schildhaus et al.
CLINICAL CANCER RESEARCH (2015)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
The Impact of Germline Genetic Variations in Hydroxysteroid (17-Beta) Dehydrogenases on Prostate Cancer Outcomes After Prostatectomy
Etienne Audet-Walsh et al.
EUROPEAN UROLOGY (2012)
High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer
Heounjeong Go et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non-Small-Cell Lung Cancer Patients
Federico Cappuzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)